Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial will evaluate the bevacizumab/erlotinib combination with the addition
of imatinib (Gleevec). The combined inhibition greatly enhances the anti-tumor effects.
Although the safety of the bevacizumab/erlotinib/imatinib combination has not yet been
demonstrated, the mild to moderate side effects of all of these agents are not predicted to
cause prohibitive toxicity. A brief phase I portion will be included in this trial, to
optimize doses of the 3 agents prior to proceeding with the phase II trial.